Ý - Tiếng Ý - AIFA (Agenzia Italiana del Farmaco)

programmi sanit.integrati srl - clotrimazolo - crema - "1% crema" tubo da 30 g - antimicotici uso dermatologico

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, timolol maleate - glaucoma, open-angle; ocular hypertension - oftalmologici - diminuzione della pressione intraoculare (pio) nei pazienti adulti con glaucoma ad angolo aperto o ipertensione oculare per i quali la monoterapia offre una riduzione della pio insufficiente.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide - glaucoma, open-angle; ocular hypertension - oftalmologici - azopt è indicato per diminuire la pressione intraoculare elevata in:ipertensione oculare;angolo aperto glaucomaas in monoterapia in pazienti adulti che non rispondono ai beta-bloccanti o nei pazienti adulti in cui i beta-bloccanti sono controindicati, o come terapia aggiuntiva ai beta-bloccanti o agli analoghi delle prostaglandine..

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infezioni da hiv - antivirali per uso sistemico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Ý - Tiếng Ý - AIFA (Agenzia Italiana del Farmaco)

teva italia s.r.l. - darunavir - darunavir

Thụy Sĩ - Tiếng Ý - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - tacrolimus - retardkapseln - tacrolimusum 0.5 mg, hypromellosum, ethylcellulosum, lactosum monohydricum 53.64 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), e 172 (flavum), natrii laurilsulfas corresp. natrium 200 ppm, drucktinte: lacca, lecithinum ex soja, simeticonum, hydroxypropylcellulosum, e 172 (rubrum), pro capsula. - immunsuppressivum - synthetika

Thụy Sĩ - Tiếng Ý - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - tacrolimus - retardkapseln - tacrolimusum 1 mg, hypromellosum, ethylcellulosum, lactosum monohydricum 107.28 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), natrii laurilsulfas corresp. natrium 200 ppm, drucktinte: lacca, lecithinum ex soja, simeticonum, hydroxypropylcellulosum, e 172 (rubrum), pro capsula. - immunsuppressivum - synthetika

Thụy Sĩ - Tiếng Ý - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - tacrolimus - retardkapseln - tacrolimusum 5 mg, hypromellosum, ethylcellulosum, lactosum monohydricum 536.4 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), natrii laurilsulfas corresp. natrium 200 ppm, drucktinte: lacca, lecithinum ex soja, simeticonum, hydroxypropylcellulosum, e 172 (rubrum), pro capsula. - immunsuppressivum - synthetika

Thụy Sĩ - Tiếng Ý - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - tacrolimus - retardkapseln - tacrolimusum 3 mg, hypromellosum, ethylcellulosum, lactosum monohydricum 321.84 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), natrii laurilsulfas corresp. natrium 200 ppm, drucktinte: lacca, lecithinum ex soja, simeticonum, hydroxypropylcellulosum, e 172 (rubrum), pro capsula. - immunsuppressivum - synthetika

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

janssen-cilag international nv - o esposti per lungo tempo, cobicistat, emtricitabina, tenofovir alafenamide - infezioni da hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza è indicato per il trattamento dell'infezione da virus dell'immunodeficienza umana di tipo 1 (hiv-1) negli adulti e negli adolescenti (di età pari o superiore a 12 anni con peso corporeo di almeno 40 kg). genotypic testing should guide the use of symtuza.